By Fineline Cube 
Gan & Lee Pharmaceuticals (SHA: 603087) announced today that it has signed a Memorandum of Understanding (MoU) with Brazil’s Oswaldo Cruz Foundation (Fiocruz), a public laboratory directly under the Brazilian Ministry of Health. The partnership will focus on the company’s late‑stage clinical portfolio, including the once‑weekly ultra‑long‑acting insulin GZR4, the once‑weekly fixed‑ratio combination GZR102, and a suite of oncology and autoimmune agents built on Gan & Lee’s mature PROTAC platform.
Key Developments
| Product | Status | Highlights |
|---|---|---|
| GZR4 | Phase III | Ultra‑long‑acting once‑weekly insulin; subcutaneous injection; stable glucose‑lowering for 7 days; aims to reduce injection burden and improve quality of life for diabetic patients. |
| GZR102 | Phase II | Fixed‑ratio combination of GZR4 (insulin) + Bonfaglutide (GLP‑1RA); once‑weekly subcutaneous; synergistic effect; lowers glucose while reducing insulin dose, hypoglycemia, and weight gain. |
| PROTAC‑Based Pipeline | Late‑stage | Novel oncology and autoimmune candidates targeting disease‑specific proteins; leveraging protein‑degradation technology. |
Strategic Implications
- Global Reach – The MoU opens a robust distribution channel in Brazil and Latin America, positioning Gan & Lee as a key player in the expanding global diabetes market.
- Accelerated Development – Fiocruz’s clinical and regulatory infrastructure will expedite late‑stage trials, potentially shortening time to market for GZR4 and GZR102.
- Platform Expansion – The partnership underscores the versatility of the PROTAC platform, extending its therapeutic scope beyond diabetes into oncology and autoimmune disease.
Forward‑looking Statements
This release contains forward‑looking statements that involve risks and uncertainties. Actual results may differ materially.-Fineline Info & Tech